V. V. Fominykh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. V. Fominykh has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- N. V. Myakova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation
10 shared publications - Yu. G. Abugova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
8 shared publications - Dmitrii Evstratov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
7 shared publications - Yu. Yu. Dyakonova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
6 shared publications Ю. Ю. Дьяконова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
6 shared publications- Dmitriy Sergeevich Abramov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
5 shared publications
Latest Publications
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
EVOLUTION OF THE DIAGNOSIS AND TREATMENT OF LYMPHOMAS IN CHILDREN IN THE RUSSIAN FEDERATION
The period from the mid-1980s to the present has been marked by significant progress in understanding the pathogenesis, diagnosis, and treatment of malignant lymphoproliferative diseases in children. Lymphomas — both Hodgkin's lymphoma and non-Hodgkin's lymphomas (NHL) — represent a significant proportion of childhood oncological diseases, accounting for 10% to 15% of all malignant neoplasms in individuals under 18 years of age. Improvements in chemotherapy protocols, the introduction of modern radiation diagnostic methods, the development of molecular genetic technologies, and the emergence of immunotherapeutic approaches have radically changed the prognosis of these diseases. While overall survival for NHL in children did not exceed 30–40% in the 1970s, by the early 2020s, 5-year survival rates for most histological variants of NHL reached 80–95%. This article focuses on the development of diagnostic and therapeutic approaches to the treatment of lymphomas in children in the Russian Federation over the past four decades.
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
EVOLUTION OF THE DIAGNOSIS AND TREATMENT OF LYMPHOMAS IN CHILDREN IN THE RUSSIAN FEDERATION
The period from the mid-1980s to the present has been marked by significant progress in understanding the pathogenesis, diagnosis, and treatment of malignant lymphoproliferative diseases in children. Lymphomas — both Hodgkin's lymphoma and non-Hodgkin's lymphomas (NHL) — represent a significant proportion of childhood oncological diseases, accounting for 10% to 15% of all malignant neoplasms in individuals under 18 years of age. Improvements in chemotherapy protocols, the introduction of modern radiation diagnostic methods, the development of molecular genetic technologies, and the emergence of immunotherapeutic approaches have radically changed the prognosis of these diseases. While overall survival for NHL in children did not exceed 30–40% in the 1970s, by the early 2020s, 5-year survival rates for most histological variants of NHL reached 80–95%. This article focuses on the development of diagnostic and therapeutic approaches to the treatment of lymphomas in children in the Russian Federation over the past four decades.
- Open Access
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 152-155
Secondary Fisher–Evans syndrome in a child with activated PI(3)kd syndrome and lymphoma
Evans syndrome, a combination of autoimmune hemolytic anemia and immune thrombocytopenia, is a rare disease in children. In childhood, it may turn out to be one of the first manifestations of a primary immunodeficiency or an immune dysregulation syndrome. Here we present a clinical case of a patient who was initially diagnosed with Evans syndrome and did not respond well to therapy. Based on the results of genetic testing, the child was then diagnosed with primary immunodeficiency, namely, activated PI(3)kd syndrome. During follow-up, the patient developed lymphoma and had to undergo radical treatment (allogeneic hematopoietic stem cell transplantation). The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 152-155
Open AccessSecondary Fisher–Evans syndrome in a child with activated PI(3)kd syndrome and lymphoma
Evans syndrome, a combination of autoimmune hemolytic anemia and immune thrombocytopenia, is a rare disease in children. In childhood, it may turn out to be one of the first manifestations of a primary immunodeficiency or an immune dysregulation syndrome. Here we present a clinical case of a patient who was initially diagnosed with Evans syndrome and did not respond well to therapy. Based on the results of genetic testing, the child was then diagnosed with primary immunodeficiency, namely, activated PI(3)kd syndrome. During follow-up, the patient developed lymphoma and had to undergo radical treatment (allogeneic hematopoietic stem cell transplantation). The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- Open Access
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 53-61
Treatment of lymphoid malignancies in patients with primary immunodeficiencies associated with DNA repair defects
Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia (AT; Louis–Bar syndrome) are primary immunodeficiencies (PID) associated with chromosome instability and DNA repair defects that predispose individuals to an increased risk of various malignancies. In our study, we retrospectively analyzed clinical characteristics and outcomes of 28 cancer cases in 14 patients with AT and 10 patients with NBS who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2007 and December 2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The most common type of malignancy was mature B-cell non-Hodgkin lymphoma (B-NHL) (42%), with diffuse large B-cell lymphoma (DLBCL) accounting for 91% of all B-NHL cases. Other cases included T-cell acute lymphoblastic leukemia (ALL) (n = 3), B-cell ALL (n = 2), Hodgkin lymphoma (n = 3), NK/T-cell lymphoma (n = 1), T-cell lymphoblastic lymphoma (n = 1), peripheral T- cell lymphoma (n = 2), medulloblastoma (n = 1) epithelioid rhabdomyosarcoma (n = 1), T-cell prolymphocytic leukemia (n = 2). A total of 4 patients were diagnosed with second malignancies (2 children with AT and 2 children with NBS. The diagnosis of PID was suspected or confirmed before the initiation of cancer therapy in 62% of AT patients and in 100% of NBS patients. Treatment was given in accordance with standard protocols with chemotherapy dose modifications. A total of 93% of patients with AT and 80% of patients with NBS required dose reduction. The level of response was quite high: 81% of patients with AT and 58% of patients with NBS achieved complete remission. According to our data, the use of reduced-dose chemotherapy regimens helps to achieve an acceptable toxicity profile without reducing the overall effectiveness of treatment.
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 53-61
Open AccessTreatment of lymphoid malignancies in patients with primary immunodeficiencies associated with DNA repair defects
Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia (AT; Louis–Bar syndrome) are primary immunodeficiencies (PID) associated with chromosome instability and DNA repair defects that predispose individuals to an increased risk of various malignancies. In our study, we retrospectively analyzed clinical characteristics and outcomes of 28 cancer cases in 14 patients with AT and 10 patients with NBS who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2007 and December 2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The most common type of malignancy was mature B-cell non-Hodgkin lymphoma (B-NHL) (42%), with diffuse large B-cell lymphoma (DLBCL) accounting for 91% of all B-NHL cases. Other cases included T-cell acute lymphoblastic leukemia (ALL) (n = 3), B-cell ALL (n = 2), Hodgkin lymphoma (n = 3), NK/T-cell lymphoma (n = 1), T-cell lymphoblastic lymphoma (n = 1), peripheral T- cell lymphoma (n = 2), medulloblastoma (n = 1) epithelioid rhabdomyosarcoma (n = 1), T-cell prolymphocytic leukemia (n = 2). A total of 4 patients were diagnosed with second malignancies (2 children with AT and 2 children with NBS. The diagnosis of PID was suspected or confirmed before the initiation of cancer therapy in 62% of AT patients and in 100% of NBS patients. Treatment was given in accordance with standard protocols with chemotherapy dose modifications. A total of 93% of patients with AT and 80% of patients with NBS required dose reduction. The level of response was quite high: 81% of patients with AT and 58% of patients with NBS achieved complete remission. According to our data, the use of reduced-dose chemotherapy regimens helps to achieve an acceptable toxicity profile without reducing the overall effectiveness of treatment.
- Open Access
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 46-52
The use of inotuzumab ozogamicin in children with relapsed/refractory B-lineage acute lymphoblastic leukemia
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse treatment is directly dependent on whether or not a tumor clone has been completely eradicated before hematopoietic stem cell transplantation (HSCT). Immunotherapy made it possible to achieve minimal residual disease (MRD) – negative remission even in refractory patients. One example of such immunotherapeutic agents is inotuzumab ozogamicin (InO), an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent calicheamicin. We included 17 patients under the age of 18 with relapsed or refractory precursor B-cell ALL (pre-B ALL) who had been treated with InO at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia from 01.10.2016 to 01.09.2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The efficacy of the therapy was assessed based on the patients’ morphological response, MRD negativity and overall survival. Treatment toxicity was assessed according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). Statistical analysis was performed using the XLSTAT 2016 software. The majority of the patients (75%) responded to the therapy. MRD negativity was achieved in 41.2% of the study patients. The one-year overall survival rate was 40.3% (95% confidence interval 14.8–65.7). The treatment was well tolerated but 33% of the patients treated with standard-dose InO and subsequent HSCT developed veno-occlusive disease/sinusoidal obstruction syndrome. In our study, we demonstrated the high efficacy of InO both when used as a rescue therapy in patients with relapsed/refractory pre-B ALL and as a bridging therapy in patients before HSCT.
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 46-52
Open AccessThe use of inotuzumab ozogamicin in children with relapsed/refractory B-lineage acute lymphoblastic leukemia
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse treatment is directly dependent on whether or not a tumor clone has been completely eradicated before hematopoietic stem cell transplantation (HSCT). Immunotherapy made it possible to achieve minimal residual disease (MRD) – negative remission even in refractory patients. One example of such immunotherapeutic agents is inotuzumab ozogamicin (InO), an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent calicheamicin. We included 17 patients under the age of 18 with relapsed or refractory precursor B-cell ALL (pre-B ALL) who had been treated with InO at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia from 01.10.2016 to 01.09.2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The efficacy of the therapy was assessed based on the patients’ morphological response, MRD negativity and overall survival. Treatment toxicity was assessed according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). Statistical analysis was performed using the XLSTAT 2016 software. The majority of the patients (75%) responded to the therapy. MRD negativity was achieved in 41.2% of the study patients. The one-year overall survival rate was 40.3% (95% confidence interval 14.8–65.7). The treatment was well tolerated but 33% of the patients treated with standard-dose InO and subsequent HSCT developed veno-occlusive disease/sinusoidal obstruction syndrome. In our study, we demonstrated the high efficacy of InO both when used as a rescue therapy in patients with relapsed/refractory pre-B ALL and as a bridging therapy in patients before HSCT.
- Open Access
- 7 October 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (3) , 46-50-50
Incidence of venous thromboembolism in children with primary lymphomas
Cancer increases the risk of venous thromboembolism (VTE) in adults and children. The aim of our study was to evaluate the incidence of VTE in children and adolescents with lymphomas. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. A retrospective analysis based on medical data of 262 children and adolescents (0–18 years) with primary lymphomas (n = 262) who were treated in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology since 01.01.2013 to 31.12.2019 had been performed. Such parameters as age and sex distribution of patients, the frequency, as well as the cumulative incidence of detection (CI) and differences in localization, the median time of detection of symptomatic (sVTE) and asymptomatic episodes of VT (aVTE), their relationship with central venous catheters (CVC) were analyzed. Statistical processing of the obtained data was carried out using the XLSTAT 2020 program (Addinsoft, France). The median age was 11,1 years (interquartile range (IQR) 6.5–15 years), the ratio of males to females was 2.2:1. There were 71 episodes of VTE in 65 patients (24.8%, 95% confidence interval (CI): 19.6–30). Among all episodes of VTE 31% were defined as sVTE at 400 day CI for sVTE was found to be 8.1% (95% CI: 5.4–12.2) and CI for aVTE – 18.7% (95% CI: 14.4–24.2). The median time to VTE episode was 38 days (IQR 16.5–91.5 days). There was a trend towards an earlier diagnosis of sVTE (median 23.5 days, IQR – 17–42 days) than aVTE (median 62 days, IQR 14–80 days), p = 0.075. VTE was CVC-related in 67.7 of all VTE cases. In one case, asymptomatic thrombosis of right atrium led to pulmonary embolism (PE). VTE is a frequent complication in children and adolescents with lymphomas. Most episodes of VTE were asymptomatic, one of which was the most likely cause of PE in the child. Further research is needed to find risk factors for VTE.
- 7 October 2021
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 20 (3) , 46-50-50
Open AccessIncidence of venous thromboembolism in children with primary lymphomas
Cancer increases the risk of venous thromboembolism (VTE) in adults and children. The aim of our study was to evaluate the incidence of VTE in children and adolescents with lymphomas. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. A retrospective analysis based on medical data of 262 children and adolescents (0–18 years) with primary lymphomas (n = 262) who were treated in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology since 01.01.2013 to 31.12.2019 had been performed. Such parameters as age and sex distribution of patients, the frequency, as well as the cumulative incidence of detection (CI) and differences in localization, the median time of detection of symptomatic (sVTE) and asymptomatic episodes of VT (aVTE), their relationship with central venous catheters (CVC) were analyzed. Statistical processing of the obtained data was carried out using the XLSTAT 2020 program (Addinsoft, France). The median age was 11,1 years (interquartile range (IQR) 6.5–15 years), the ratio of males to females was 2.2:1. There were 71 episodes of VTE in 65 patients (24.8%, 95% confidence interval (CI): 19.6–30). Among all episodes of VTE 31% were defined as sVTE at 400 day CI for sVTE was found to be 8.1% (95% CI: 5.4–12.2) and CI for aVTE – 18.7% (95% CI: 14.4–24.2). The median time to VTE episode was 38 days (IQR 16.5–91.5 days). There was a trend towards an earlier diagnosis of sVTE (median 23.5 days, IQR – 17–42 days) than aVTE (median 62 days, IQR 14–80 days), p = 0.075. VTE was CVC-related in 67.7 of all VTE cases. In one case, asymptomatic thrombosis of right atrium led to pulmonary embolism (PE). VTE is a frequent complication in children and adolescents with lymphomas. Most episodes of VTE were asymptomatic, one of which was the most likely cause of PE in the child. Further research is needed to find risk factors for VTE.
- Open Access
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 43-48
Results of multicenter international trail for pediatric primary mediastinal B-cell lymphoma treated according to protocols B-NHL-M-10 and DA-EPOCH-R
During last years dose-adjusted EPOCH chemotherapy has become the most common international fist-line regimen of treatment of primary mediastinal B-cell lymphoma ^МВ^). Our goal is to evaluate results of multicentre international trail of treatment for children with PMBCL according to B-NHL-М-Ю and with dose-adjusted EPOCH protocol. This study was supported by the Independent Ethical Committee of State Nature Research Institute and approved by the decision of the Academic Council. More than 20 clinics from Russian Federetion and republic of Belarus are involved in this reaserch. Since January 2011 to June 2017 246 patients with first diagnosed NHL were included in the study, 18 of them had PMBCL (7.3%). Results: 10 patients (55.5%) were treated according to BNHL protocol, 8 (44.4%) patients received Dа-EPOCH-R protocol. With median follow-up of 3-year, EFS for patients with treatment according to B-NHL-М-Ю protocol was 70% for other with Dа-EPOCH-R - 67%.
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 43-48
Open AccessResults of multicenter international trail for pediatric primary mediastinal B-cell lymphoma treated according to protocols B-NHL-M-10 and DA-EPOCH-R
During last years dose-adjusted EPOCH chemotherapy has become the most common international fist-line regimen of treatment of primary mediastinal B-cell lymphoma ^МВ^). Our goal is to evaluate results of multicentre international trail of treatment for children with PMBCL according to B-NHL-М-Ю and with dose-adjusted EPOCH protocol. This study was supported by the Independent Ethical Committee of State Nature Research Institute and approved by the decision of the Academic Council. More than 20 clinics from Russian Federetion and republic of Belarus are involved in this reaserch. Since January 2011 to June 2017 246 patients with first diagnosed NHL were included in the study, 18 of them had PMBCL (7.3%). Results: 10 patients (55.5%) were treated according to BNHL protocol, 8 (44.4%) patients received Dа-EPOCH-R protocol. With median follow-up of 3-year, EFS for patients with treatment according to B-NHL-М-Ю protocol was 70% for other with Dа-EPOCH-R - 67%.
- Open Access
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 81-87
Panniculitis-like T-cell lymphoma in children
Subcutaneous panniculitis-like T-cell lymphoma is a rare form of peripheral T-cell lymphoma. The frequency of occurrence of this pathology is 1% of all primary T-cell lymphomas of the skin, at that 20% of all population are children and adolescents, in this way, the percentage of occurrence of this type of tumor in the pediatric population is less than 1%. Given the rarity of pathology, there is no single tactic of therapy and an assessment of its effectiveness. This article presents a review of the literature on the description, diagnosis, and treatment of panniculitis-like T-cell lymphoma. It also presents a clinical case of the development of this type of lymphoma in a 3-year-old child, with a progressive course and subsequent HScT from a haploinentical relative donor.Patient's parents agreed to use personal dats and photos in research and publications.
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 81-87
Open AccessPanniculitis-like T-cell lymphoma in children
Subcutaneous panniculitis-like T-cell lymphoma is a rare form of peripheral T-cell lymphoma. The frequency of occurrence of this pathology is 1% of all primary T-cell lymphomas of the skin, at that 20% of all population are children and adolescents, in this way, the percentage of occurrence of this type of tumor in the pediatric population is less than 1%. Given the rarity of pathology, there is no single tactic of therapy and an assessment of its effectiveness. This article presents a review of the literature on the description, diagnosis, and treatment of panniculitis-like T-cell lymphoma. It also presents a clinical case of the development of this type of lymphoma in a 3-year-old child, with a progressive course and subsequent HScT from a haploinentical relative donor.Patient's parents agreed to use personal dats and photos in research and publications.
- Open Access
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 96-103
Hepatosplenic γδ T-cell lymphoma in a 4 years old child
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that characterized by proliferation in the liver, spleen and bone marrow. The article presents analytical review of literature and the clinical case of γδ HSTCL in 4 years old child. Patient's parents agreed to use personal dats and photos in research and publications.
- 21 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 96-103
Open AccessHepatosplenic γδ T-cell lymphoma in a 4 years old child
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that characterized by proliferation in the liver, spleen and bone marrow. The article presents analytical review of literature and the clinical case of γδ HSTCL in 4 years old child. Patient's parents agreed to use personal dats and photos in research and publications.
- Open Access
- 20 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 12-21
First results of pilot protocol ALl-REZ-2016 for children with high risk groups of relapsed acute lymphoblastic leukemia
Despite remarksble improvements in the treatment of pediatric acute limphoblastic leukemia (ALL) over last decades, relapse still caries a poor prognosis with considerable morbidity and mortality. New strategies and approaches are extremely needed. According to the results of previous protocol ALL-REZ-2014 despite the implementation of bortezomib, as well as idarubicin and navelbine, which have not been used in first-line therapy, the new protocol had demonstrated no significant improvement in reaching a steady remission, especially for B-ALL relapses. The therapy results for the high risk group patients still far from optimal due to refractoriness to chemotherapy, death from infectious complications, as well as acute chemotherapy toxicity. This article demonstrates first results of pilot protocol All-REZ-2016 for high risk ALL relapses, which was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. Between 01.08.2016 and 01.12.2018 42 patients from our center were enrolled in ALL-REZ-2016 study. Patients aged 1-18 years with a first relapse of ALL without t(9;22) translocation were eligible , we included only high risk groups (S3, S4, S5) patients in this study. CD3+ apheresis was made before treatment for all patients with B-cell phenotype. To determine the efficiency and toxicity of fludarabine- and clofarabine-including chemotherapy regimens after the preliminary phase with prednisone 60mg/m2, for patients with B-ALL randomization for blocks with fludarabine or clofarabine was performed. The next stage of the therapy was a course with blinatumomab (28 days) and weekly autologous lymphocyte infusions (x 4). ALL patients with T-ALL got 11 days of protocol N, and then studying the efficiency of clofarabine 52 mg/m2 for TIII/TIV was planned, since nelarabine has been shown to be inefficient for this category. For the patients with TI/II ALL, nelarabine 650 mg/m2 therapy was given after protocol N. If remission was attained, a stem cell transplant was performed for all patients without delay. 42 patients were enrolled, the median age was 9.9 years (range 2.7-16.2), there was male predominance (63.8%), the majority had B-cell phenotype (61.7%). The estimated 2-year event-free survival (EFS) across all immunophenotypes was 47.7% (SE+/-8%) and a cumulative incidence of second relapse (CIR) was 27.1% (SE+/-7.6%). Patients with B-ALL had EFS 55% +/-10% and CIR 30.0% +/-9.9%, T-ALL had EFS 35% +/-13% and CIR 21.2+/-12%. We did not observe serious toxicity when using blinatumomab. The use of clofarabine and fludarabine was accompanied by deep immunosuppression and severe infectious episodes. Results for patients with B-cell relapses are much better then in previous protocol ALL-REZ-2014, using of autologous CD3+ lymphocytes infusion once a week during the continuous blinatumomab therapy is effective. For T-ALL relapses results remain unsatisfactory due to refractoriness, but number of patients is still small for final conclusions.
- 20 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 12-21
Open AccessFirst results of pilot protocol ALl-REZ-2016 for children with high risk groups of relapsed acute lymphoblastic leukemia
Despite remarksble improvements in the treatment of pediatric acute limphoblastic leukemia (ALL) over last decades, relapse still caries a poor prognosis with considerable morbidity and mortality. New strategies and approaches are extremely needed. According to the results of previous protocol ALL-REZ-2014 despite the implementation of bortezomib, as well as idarubicin and navelbine, which have not been used in first-line therapy, the new protocol had demonstrated no significant improvement in reaching a steady remission, especially for B-ALL relapses. The therapy results for the high risk group patients still far from optimal due to refractoriness to chemotherapy, death from infectious complications, as well as acute chemotherapy toxicity. This article demonstrates first results of pilot protocol All-REZ-2016 for high risk ALL relapses, which was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. Between 01.08.2016 and 01.12.2018 42 patients from our center were enrolled in ALL-REZ-2016 study. Patients aged 1-18 years with a first relapse of ALL without t(9;22) translocation were eligible , we included only high risk groups (S3, S4, S5) patients in this study. CD3+ apheresis was made before treatment for all patients with B-cell phenotype. To determine the efficiency and toxicity of fludarabine- and clofarabine-including chemotherapy regimens after the preliminary phase with prednisone 60mg/m2, for patients with B-ALL randomization for blocks with fludarabine or clofarabine was performed. The next stage of the therapy was a course with blinatumomab (28 days) and weekly autologous lymphocyte infusions (x 4). ALL patients with T-ALL got 11 days of protocol N, and then studying the efficiency of clofarabine 52 mg/m2 for TIII/TIV was planned, since nelarabine has been shown to be inefficient for this category. For the patients with TI/II ALL, nelarabine 650 mg/m2 therapy was given after protocol N. If remission was attained, a stem cell transplant was performed for all patients without delay. 42 patients were enrolled, the median age was 9.9 years (range 2.7-16.2), there was male predominance (63.8%), the majority had B-cell phenotype (61.7%). The estimated 2-year event-free survival (EFS) across all immunophenotypes was 47.7% (SE+/-8%) and a cumulative incidence of second relapse (CIR) was 27.1% (SE+/-7.6%). Patients with B-ALL had EFS 55% +/-10% and CIR 30.0% +/-9.9%, T-ALL had EFS 35% +/-13% and CIR 21.2+/-12%. We did not observe serious toxicity when using blinatumomab. The use of clofarabine and fludarabine was accompanied by deep immunosuppression and severe infectious episodes. Results for patients with B-cell relapses are much better then in previous protocol ALL-REZ-2014, using of autologous CD3+ lymphocytes infusion once a week during the continuous blinatumomab therapy is effective. For T-ALL relapses results remain unsatisfactory due to refractoriness, but number of patients is still small for final conclusions.
- Open Access
- 20 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 49-54
Efficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol
The reduction of long-term survival and fertility is still a problem in management of Hodgkin lymphoma in children and adolescents. These problems are partly solved by reduction of radiotherapy and changing procarbazine on etoposide and dacarbazine. We analyzed medical data of patients with HL 18 years that were treated by modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. All patients despite gender didn't receive procarbazine. We analyzed data of 77 patients. Event-free survival (EFS) was 88% (95% CI 76.2-93.9%). EFS didn't differ between boys and girls 86.9% (95% CI 67.8-94.7%) and 88.7% (95% CI 67.3-96.1%) respectively (р = 0,9). EFS was significantly higher in patients without E-lesions compared with patients with E-lesions 90.8% (95% CI 77.8-96.2) and 72.7% (95% CI 28.4-89.6) respectively (p = 0.04). We analyzed toxicity of 40 cycles OEPA and 44 cycles COPDAC. Toxicity was acceptable. In our study we didn't detect significant difference in EFS in boys and girls. Procarbazine can be safely changed on etoposide in OPPA and dacarbazine in COPP in boys and girls with HL. E-lesions is a risk factor of inferior EFS.
- 20 April 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (1) , 49-54
Open AccessEfficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol
The reduction of long-term survival and fertility is still a problem in management of Hodgkin lymphoma in children and adolescents. These problems are partly solved by reduction of radiotherapy and changing procarbazine on etoposide and dacarbazine. We analyzed medical data of patients with HL 18 years that were treated by modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. All patients despite gender didn't receive procarbazine. We analyzed data of 77 patients. Event-free survival (EFS) was 88% (95% CI 76.2-93.9%). EFS didn't differ between boys and girls 86.9% (95% CI 67.8-94.7%) and 88.7% (95% CI 67.3-96.1%) respectively (р = 0,9). EFS was significantly higher in patients without E-lesions compared with patients with E-lesions 90.8% (95% CI 77.8-96.2) and 72.7% (95% CI 28.4-89.6) respectively (p = 0.04). We analyzed toxicity of 40 cycles OEPA and 44 cycles COPDAC. Toxicity was acceptable. In our study we didn't detect significant difference in EFS in boys and girls. Procarbazine can be safely changed on etoposide in OPPA and dacarbazine in COPP in boys and girls with HL. E-lesions is a risk factor of inferior EFS.